THERAPIES FOR CHRONIC MYELOID LEUKAEMIA
Professor Tim Hughes
Clinical Director Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute (SAHMRI)
& Consultant Haematologist, Royal Adelaide Hospital, South Australia
RESEARCHER PROFILE (Filmed in Adelaide, South Australia | December 2024)
Professor Tim Hughes is the Chronic Myeloid Leukaemia Group Leader at SAHMRI, Clinical Director in the Precision Cancer Medicine Theme at SAHMRI and Consultant Haematologist in the Division of Haematology at SA Pathology and at the Royal Adelaide Hospital.
He is also Inaugural Fellow of the Australian Academy of Health and Medical Sciences (AAHMS) and Fellow of the Australian Academy of Science.
Professor Hughes is an international expert in the biology and treatment of leukaemia. He led the establishment of the molecular response criteria that are used world-wide to measure response in chronic myeloid leukaemia (CML) and has led many of the key Global and National trials. His group has successfully developed predictive bioassays and molecular targets that influence the way CML patients are managed world-wide. He has published over 350 papers that have been cited over 65,000 times.
He has been recognised for his achievements with several national awards including the GSK Award for Research Excellence in 2017 for pioneering the use of tyrosine kinase inhibitors (TKIs) and the Ramaciotti Medal for Excellence in Biomedical Research in 2019. He was also awarded the International CML Foundation Goldman Prize in 2017 for lifetime contributions to improving outcomes for patients with CML.
-
Benefits of prehabilitation ahead of surgery
Dr Matthew Wallen PhD, AES, AEP is a Senior Research Fellow in Cancer Survivorship, the Deputy Lead of the Cancer Survivorship Program, and a Senior Lecturer in Exercise Science and Clinical Exercise Physiology within the College of Nursing and Health Sciences at Flinders University, in South Australia. His clinical interest focuses on improving outcomes for people requiring major surgery, specifically (1) lifestyle interventions, including exercise, nutritional, and psychological support to improve the health and wellbeing of people prior to surgery, termed ‘prehabilitation’, (2) novel physical function assessments aimed at identifying people at risk of treatment-related complications, and (3) implementation of new models of care in cancer.
-
Neuroscience, neuropharmacology and exercise science
Dr Jacob Thorstensen is an early-career Assistant Professor in Neuroscience and Physiology in the Faculty of Health Sciences & Medicine at Bond University. He is also an honorary research fellow in The School of Biomedical Sciences at The University of Queensland. His work has unveiled several new neuroscientific mechanisms which have future applications for movement disorders.
-
Development of novel analytical and diagnostic tools using nanotechnology and microfluidics
Dr Alain Wuethrich is an NHMRC Emerging Leader fellow and ARC DECRA awardee at the Australian Institute for Bioengineering and Nanotechnology.
Hailing from Switzerland, research focuses on the development of novel analytical and diagnostic tools that harness nanotechnology and microfluidics; two rapidly growing fields with high potential to provide diagnostic solutions needed for precision medicine.
